PACB Pacific Biosciences Of California Inc

Price (delayed)

$4.74

Market cap

$1.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.83

Enterprise value

$1.59B

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a ...

Highlights
Pacific Biosciences Of California's gross profit has surged by 58% YoY and by 2% QoQ
The revenue has increased by 46% YoY and by 3.2% QoQ
PACB's net income has shrunk by 196% YoY but it is up by 3.3% QoQ
The company's equity has surged by 162% YoY but it fell by 7% QoQ

Key stats

What are the main financial stats of PACB
Market
Shares outstanding
224.38M
Market cap
$1.06B
Enterprise value
$1.59B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.43
Price to sales (P/S)
7.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.78
Earnings
Revenue
$134.69M
EBIT
-$254.5M
EBITDA
-$241.12M
Free cash flow
-$176.27M
Per share
EPS
-$0.83
Free cash flow per share
-$0.79
Book value per share
$3.32
Revenue per share
$0.61
TBVPS
$5.02
Balance sheet
Total assets
$1.94B
Total liabilities
$1.2B
Debt
$952.02M
Equity
$734.58M
Working capital
$968.18M
Liquidity
Debt to equity
1.3
Current ratio
16.87
Quick ratio
16.25
Net debt/EBITDA
-2.17
Margins
EBITDA margin
-179%
Gross margin
44.6%
Net margin
-130.1%
Operating margin
-188.7%
Efficiency
Return on assets
-9.7%
Return on equity
-26.7%
Return on invested capital
-15.6%
Return on capital employed
-13.6%
Return on sales
-189%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PACB stock price

How has the Pacific Biosciences Of California stock price performed over time
Intraday
-2.47%
1 week
-2.67%
1 month
-23.18%
1 year
-86.84%
YTD
-76.83%
QTD
-47.91%

Financial performance

How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$134.69M
Gross profit
$60.04M
Operating income
-$254.17M
Net income
-$175.29M
Gross margin
44.6%
Net margin
-130.1%
PACB's net income has shrunk by 196% YoY but it is up by 3.3% QoQ
The company's operating income has shrunk by 141% YoY and by 21% QoQ
The net margin has dropped by 103% year-on-year but it is up by 6% since the previous quarter
PACB's operating margin has dropped by 65% year-on-year and by 18% since the previous quarter

Growth

What is Pacific Biosciences Of California's growth rate over time

Valuation

What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
1.43
P/S
7.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.78
The EPS has grown by 7% from the previous quarter
The company's equity has surged by 162% YoY but it fell by 7% QoQ
The P/B is 86% below the last 4 quarters average of 10.3 and 85% below the 5-year quarterly average of 10.0
The price to sales (P/S) is 79% lower than the last 4 quarters average of 38.8 and 60% lower than the 5-year quarterly average of 20.0
The revenue has increased by 46% YoY and by 3.2% QoQ

Efficiency

How efficient is Pacific Biosciences Of California business performance
The company's return on invested capital fell by 21% YoY but it rose by 8% QoQ
The ROE has grown by 20% from the previous quarter and by 11% YoY
PACB's ROA is up by 13% from the previous quarter and by 11% YoY
The ROS has grown by 6% from the previous quarter

Dividends

What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PACB.

Financial health

How did Pacific Biosciences Of California financials performed over time
The company's total assets is 61% higher than its total liabilities
The company's total assets has surged by 55% YoY but it fell by 3.5% QoQ
The quick ratio has plunged by 53% YoY but it has grown by 9% from the previous quarter
The debt is 30% greater than the equity
The company's equity has surged by 162% YoY but it fell by 7% QoQ
The company's debt to equity has shrunk by 61% YoY but it rose by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.